Investigating the Acceptance and Performance of Low Energy Audio Streaming in Nucleus 8 and Kanso 3 Sound Processors by Experienced Cochlear Implant Users

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCochlear

About this trial

This study aims to investigate acceptance and performance of the Bluetooth Low Energy Audio-enabled (LE Audio) firmware in the Nucleus 8 Processing Unit, Kanso 3 Nexa Sound Processor, and the Kanso 3 Sound Processor. The investigation includes actual use (take home) of LE Audio firmware releases and the new GN ReSound LE Audio wireless accessories, including the Multi-Mic+, for use in the real-world. Using the final versions of firmware, speech perception performance in noise will be investigated using the Nucleus 8 and Kanso 3 Sound Processors streaming via a Multi-Mic+.

Eligibility criteria

Qualifiers

Aged 18 years or older

Implanted with at least one of the CI1000 Series, CI600 Series, CI500 Series, Freedom Series or N24 Series cochlear hearing implants.

At least 3 months experience with a cochlear hearing implant

Demonstrated ability to score 30% or more at +15 SNR with Cochlear implant alone on a sentence in noise test.

Disqualifiers

Additional disabilities that would prevent participation in evaluations

Unrealistic expectations on the part of the participant, regarding the possible benefits, risks and limitations that are inherent to the procedures

Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator.

Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling.

Trial design

Treatments tested in this trial

  • Nucleus 8 Sound Processor streaming via MultiMic+
  • Nucleus 8 Sound Processor microphones
  • Nucleus 8 Sound Processor streaming via Roger 20
  • Kanso 3 Sound Processor streaming via Multi-Mic+
  • Kanso 3 Sound Processor microphone

Treatment groups

20 Participants
are divided into 1 treatment group

Sponsors and collaborators